LL22NC03-N14H11.1 regulates the m6A modification of MYC and promotes glycolytic activity in hepatocellular carcinoma cells by inhibiting IGF2BP3 ubiquitination degradation
The LL22NC03-IGF2BP3-MYC regulatory axis is critically involved in the progression of HCC, suggesting its potential as a novel therapeutic target for this malignancy.
Authors
- Yulu Ye
- Jiegang Huang (ORCID: https://orcid.org/0000-0003-3271-1694)
- Tingzhuang Yi (ORCID: https://orcid.org/0000-0002-4709-7247)
- Lin Cheng (ORCID: https://orcid.org/0000-0002-4960-8186)
- Huafu Li (ORCID: https://orcid.org/0009-0004-9465-1281)
- Shengkui Tan (ORCID: https://orcid.org/0000-0002-1955-0868)
- Ye Xia (ORCID: https://orcid.org/0000-0002-4749-3119)
- Meini Pan
- Jinyan Lan
- Wanlin Yang (ORCID: https://orcid.org/0000-0001-6048-0868)
- Yong‐Xia Wang (ORCID: https://orcid.org/0000-0002-0870-4200)
- Juan He (ORCID: https://orcid.org/0000-0001-7060-086X)
- Dongdong Ning (ORCID: https://orcid.org/0000-0001-8015-0831)
- Zhongheng Wei (ORCID: https://orcid.org/0000-0002-4482-0428)
- Cheng Yuan
Institutions
- Guangxi Medical University (CN)
- China Three Gorges University (CN)
- Guilin Medical University (CN)
- Wuhan University (CN)
- The Fifth People's Hospital of Anyang (CN)
- Affiliated Hospital of Youjiang Medical University for Nationalities (CN)
- Renmin Hospital of Wuhan University (CN)
- Baise University (CN)
- Yichang Central People's Hospital (CN)
- Hubei Cancer Hospital (CN)
- Imperial College London (GB)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2025-12-02
- DOI
- https://doi.org/10.1186/s13046-025-03606-1
- Primary Topic
- RNA modifications and cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00